elisidepsin

Elisidepsin (PM02734) is a synthetic cyclic depsipeptide of the kahalalide family derived from a marine metabolite originally isolated from the sea slug Elysia rufescens. It exhibits broad-spectrum antineoplastic activity against various tumor types including breast, colon, pancreas, lung, and prostate cancers. The drug induces cell death primarily through mechanisms involving autophagy rather than classical apoptosis. Specifically, it impairs autophagic flux and inhibits the Akt/mTOR signaling pathway while activating death-associated protein kinase (DAPK). Elisidepsin has been evaluated in phase I and II clinical trials for advanced solid tumors and non-small-cell lung cancer[2][4][8][10].

Brand names

Irvalec

Other names

elisidepsinPM02734PM-02734PM 02734Irvalec